Cardiff Oncology DEF 14A: Executive Compensation Details
Ticker: CRDF · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1213037
| Field | Detail |
|---|---|
| Company | Cardiff Oncology, Inc. (CRDF) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, corporate-governance
TL;DR
Cardiff Oncology dropped its 14A filing detailing exec comp for 2022-2024. Equity awards are the focus.
AI Summary
Cardiff Oncology, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation for the fiscal years ending December 31, 2022, 2023, and 2024. The filing includes information on equity awards granted and vested to both PEO (Principal Executive Officer) and Non-PEO NEO (Non-Principal Executive Officer Named Executive Officer) members. Specific dollar amounts and dates related to these awards are provided within the summary compensation tables.
Why It Matters
This filing provides transparency into how Cardiff Oncology compensates its top executives, which can influence investor decisions and perceptions of the company's financial health and management.
Risk Assessment
Risk Level: medium — DEF 14A filings, while routine, can reveal significant information about executive compensation and corporate governance that may impact stock price.
Key Numbers
- 2022-2024 — Fiscal Years Covered (Executive compensation data presented for these years.)
Key Players & Entities
- Cardiff Oncology, Inc. (company) — Filer of the DEF 14A
- 20250429 (date) — Filing date of the DEF 14A
- December 31, 2022 (date) — Fiscal year end
- December 31, 2023 (date) — Fiscal year end
- December 31, 2024 (date) — Fiscal year end
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing is a definitive proxy statement filed by a company with the SEC when soliciting shareholder votes, often detailing executive compensation, director information, and other corporate governance matters.
What specific compensation details are provided for Cardiff Oncology's executives?
The filing provides details on equity awards granted and vested for PEO and Non-PEO NEO members for the fiscal years ending December 31, 2022, 2023, and 2024, including their fair value.
What does 'PEO' and 'Non-PEO NEO' refer to in this filing?
PEO stands for Principal Executive Officer, and NEO stands for Named Executive Officer. Non-PEO NEO refers to Named Executive Officers who are not the Principal Executive Officer.
What was Cardiff Oncology's former company name?
Cardiff Oncology, Inc. was formerly known as Trovagene, Inc. (name change effective March 4, 2013) and prior to that, XENOMICS INC (name change effective July 19, 2004).
What is the business address and phone number for Cardiff Oncology?
The business address is 11055 Flintkote Avenue, San Diego, CA 92121, and the business phone number is 858-952-7570.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Cardiff Oncology, Inc. (CRDF).